Date of Deposit: February 27, 2008 Attorney Docket No.: 2582-016

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Bergmann et al.

APPLICATION NO.: 10/511.758 EXAMINER: Christina Borgeest

FILING DATE: May 25, 2005 ART UNIT: 1649

TITLE: METHOD FOR DIAGNOSING INFLAMMATORY DISEASES AND INFECTIONS BY

THE DETERMINATION OF LASP-1 IMMUNOREACTIVITY

## MAIL STOP RCE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§ 1.56, 1.97, and 1.98, Applicants hereby make of record in the instant application the documents listed on the attached Form 1449.

This Supplemental Information Disclosure Statement is filed concurrently with a Request for Continued Examination, there being a Notice of Allowance in the instant application. Accordingly, no fee for the IDS is believed due. This information is being cited out of an abundance of caution in view of the decisions in Akron Polymer Container v. Exxel Container, 148 F.3d 1380 (Fed. Cir. 1998) and McKesson Information Solutions v. Bridge Medical, Inc., 487 F.3d 897 (Fed. Cir. 2007).

Applicants respectfully request that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning patentability of the present claims, and initial, sign, and date the enclosed Form 1449, and return a copy of the signed Form 1449 with the next U.S. Patent and Trademark communication to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

Bergmann et al. U.S.S.N.: 10/511,758

Dated: February 27, 2008

By citing these references, Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b); and (3) the information cited is, or is considered to be, in fact, prior art as defined by 35 U.S.C. § 102.

Notwithstanding any statements by Applicants, or treatment of this cited information by this or another Patent Office, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited references. An early and favorable action is hereby requested.

The Commissioner is hereby authorized to charge payment of any fees that may be required, or credit any overpayment of same, to Deposit Account No. 08-1935, Reference No. 2582.016.

Respectfully submitted,

Charles E. Bell, Reg. No. 48,128

Attorney for Applicants

Heslin Rothenberg Farley & Mesiti P.C.

la S Rell

Telephone: (518) 452-5600 Facsimile: (518) 452-5579 Customer Number 23405